Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Relapsing Giant Cell Arteritis
NCT03026504Phase 2Completed
- Start
- Mar 2017
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in giant cell arteritis (GCA). Started Mar 2017; status: completed.
02
Drugs
baricitinib
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT03026504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03026504.